Trastuzumab, an important chemotherapy drug in the treatment of HER2+ cancers, has been shown to have enhanced potency when paired with the analog SAL003 in resistant HER2+ gastric and breast cancer (166). Here, ERBB2 is linked to breast carcinoma.